Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
CGEM 
Cullinan Oncology LLC (CGEM)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
07/14/2025: CGEM (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
9 Analysts rated it
Limited analyst coverage, niche firm, research info may be scarce.
1 Year Target Price $26.88
1 Year Target Price $26.88
| 8 | Strong Buy |
| 1 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -3.04% | Avg. Invested days 29 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 07/14/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 454.41M USD | Price to earnings Ratio - | 1Y Target Price 26.88 |
Price to earnings Ratio - | 1Y Target Price 26.88 | ||
Volume (30-day avg) 9 | Beta -0.04 | 52 Weeks Range 6.85 - 21.01 | Updated Date 07/14/2025 |
52 Weeks Range 6.85 - 21.01 | Updated Date 07/14/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -2.77 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -25.38% | Return on Equity (TTM) -36.57% |
Valuation
Trailing PE - | Forward PE 6.3 | Enterprise Value 152425935 | Price to Sales(TTM) 26.88 |
Enterprise Value 152425935 | Price to Sales(TTM) 26.88 | ||
Enterprise Value to Revenue 11.55 | Enterprise Value to EBITDA -1.46 | Shares Outstanding 59014700 | Shares Floating 38999253 |
Shares Outstanding 59014700 | Shares Floating 38999253 | ||
Percent Insiders 4.55 | Percent Institutions 116.27 |
Upturn AI SWOT
Cullinan Oncology LLC
Company Overview
History and Background
Cullinan Oncology, Inc. is a biopharmaceutical company founded in 2016, focused on developing a diversified portfolio of targeted and immuno-oncology therapies with the potential to address unmet medical needs in cancer. They aim to build a pipeline of assets that are strategically aligned, scientifically sound, and clinically transformative.
Core Business Areas
- Drug Development: Focuses on researching, developing, and commercializing innovative oncology therapies.
- Immuno-Oncology: Development of immunotherapies that harness the body's immune system to fight cancer.
- Targeted Therapies: Development of targeted therapies that selectively attack cancer cells while minimizing damage to healthy cells.
Leadership and Structure
Owen Hughes is the Chief Executive Officer. The company has a board of directors overseeing its strategic direction. The organizational structure includes research and development, clinical operations, and commercialization teams.
Top Products and Market Share
Key Offerings
- CLN-081 (Elias):: An EGFR inhibitor for NSCLC patients with EGFR exon 20 insertion mutations. Currently in clinical development. Market share data is not publicly available. Key competitors include TAK-788 (Mobocertinib, Takeda) and poziotinib (Spectrum Pharmaceuticals, now Acquired by Acrotech Biopharma).
- CLN-619: A MICA/B-targeted antibody-drug conjugate (ADC) designed to selectively target and eliminate cancer cells expressing MICA/B. Currently in clinical development. No market share data is available at this stage. Competitors include companies developing other ADCs.
Market Dynamics
Industry Overview
The oncology market is characterized by intense competition, high R&D costs, and stringent regulatory requirements. There's a growing demand for personalized medicine and targeted therapies.
Positioning
Cullinan Oncology is positioned as an innovative biopharmaceutical company focused on developing next-generation cancer therapies. Its competitive advantage lies in its diversified pipeline and experienced management team.
Total Addressable Market (TAM)
The global oncology market is projected to reach hundreds of billions of dollars. Cullinan Oncology targets specific segments within this large market, focusing on areas with unmet needs, like EGFR exon 20 insertion mutations in NSCLC. The success of clinical trials will dictate the market share captured.
Upturn SWOT Analysis
Strengths
- Diversified pipeline of oncology assets
- Experienced management team
- Strong financial backing
- Focus on innovative therapeutic modalities
Weaknesses
- Reliance on successful clinical trial outcomes
- High cash burn rate associated with drug development
- Limited commercialization experience
- Early stage of development for most pipeline assets
Opportunities
- Partnerships with larger pharmaceutical companies
- Expansion of pipeline through acquisitions or licensing
- Positive clinical trial results leading to regulatory approvals
- Growing demand for targeted cancer therapies
Threats
- Clinical trial failures
- Regulatory hurdles and delays
- Competition from established pharmaceutical companies
- Patent expirations and generic competition
Competitors and Market Share
Key Competitors
- TAK (TAKeda)
- SPPI (Spectrum Pharmaceuticals)
- MRTX (Mirati Therapeutics)
- BLU (Blueprint Medicines)
Competitive Landscape
Cullinan Oncology faces competition from established pharmaceutical companies with greater resources and commercialization experience. Its advantage lies in its innovative pipeline and focus on specific cancer targets.
Growth Trajectory and Initiatives
Historical Growth: Historical growth is reflected in the expansion of the pipeline and increased R&D spending.
Future Projections: Future growth depends on successful clinical trial outcomes, regulatory approvals, and commercialization of its assets. Analyst estimates vary based on the potential of its pipeline.
Recent Initiatives: Recent initiatives include advancing clinical trials for CLN-081 and CLN-619, and evaluating new drug candidates.
Summary
Cullinan Oncology is a development-stage biopharmaceutical company with a promising pipeline of oncology assets. Its success depends on positive clinical trial results and regulatory approvals. The company faces significant competition and high R&D costs but has the potential to address unmet medical needs in cancer. They need to ensure they have solid financial backing to get their products to market. Clinical trial success is their key to the future.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company website
- SEC filings
- Analyst reports
- Industry publications
Disclaimers:
This analysis is for informational purposes only and should not be considered investment advice. Market share estimates are approximate and may vary depending on the source. Financial data is based on publicly available information and may be subject to change.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Cullinan Oncology LLC
Exchange NASDAQ | Headquaters Cambridge, MA, United States | ||
IPO Launch date 2021-01-08 | President, CEO & Director Mr. Nadim Ahmed | ||
Sector Healthcare | Industry Biotechnology | Full time employees 111 | Website https://cullinantherapeutics.com |
Full time employees 111 | Website https://cullinantherapeutics.com | ||
Cullinan Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops therapies for autoimmune diseases and cancer in the United States. The company develops zipalertinib, a bioavailable small molecule in Phase 3 trial for the treatment of patients with non-small cell lung cancer; CLN-978, a T cell engager to treat systemic lupus erythematosus and rheumatoid arthritis; and CLN-619, a monoclonal antibody in Phase 1 trial for the treatment of solid tumors and multiple myeloma. Its development products also include CLN-049, a humanized bispecific antibody in Phase 1 trial for the treatment of acute myeloid leukemia (AML) or myelodysplastic syndrome, as well as measurable residual disease positive AML; and CLN-617, a fusion protein in Phase 1 trial for the treatment of solid tumors. It has a collaboration agreement with Adimab, LLC to discover and/or optimize antibodies; and co-development agreement with Taiho Pharmaceutical Co., Ltd to develop zipalertinib. The company was formerly known as Cullinan Oncology, Inc. and changed its name to Cullinan Therapeutics, Inc. in April 2024. Cullinan Therapeutics, Inc. was incorporated in 2016 and is headquartered in Cambridge, Massachusetts.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.